- Home
- EXFY vs UNCY Comparison
EXFY vs UNCY Comparison
Compare EXFY & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXFY | UNCY |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.1M | 145.3M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EXFY | UNCY |
|---|---|---|
| Price | $0.83 | $6.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $4.50 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 983.6K | 437.5K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $142,101,000.00 | $675,000.00 |
| Revenue This Year | $0.42 | N/A |
| Revenue Next Year | $0.11 | $407.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.06 | N/A |
| 52 Week Low | $0.69 | $0.45 |
| 52 Week High | $3.06 | $7.57 |
Technical Indicators
Market Signals| Indicator | EXFY | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 40.74 | 48.32 |
| Support Level | $0.73 | $6.48 |
| Resistance Level | $0.93 | $7.04 |
| Average True Range (ATR) | 0.08 | 0.39 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 58.95 | 39.07 |
Price Performance
Historical ComparisonAbout EXFY Expensify Inc.
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.